Vorinostat is a class I/II HDAC inhibitor, which has activity against neuroblastoma cells as a single agent, as well as in combination with the standard-of-care chemotherapy drug doxorubicin and with radiotherapy (26). Here, HDAC9 is linked to neuroblastoma.